A1C, LDL, HDL… the number of medical abbreviations you might see on your patient portal is enough to make you think your doctor speaks an entirely different language. Two such acronyms you may be less ...

Strategic collaboration expands taletrectinib global reach with a leading oncology partnerEisai will receive exclusive development, registration and commercialization rights for taletrectinib for the ...

Nuvation Bio Inc. , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced preliminary fourth quarter and full year 2025 net product revenue ...

The recurring problems with AI Overviews stem from a design flaw in how the system works. As we reported in May 2024, Google ...

This mind-blowing study revealed how berberine lowers LDL cholesterol through a mechanism that’s completely different from ...

How weight loss and diet changes show up in lab results Weight loss creates measurable improvements in lab work that doctors track regularly throughout your journey.

Truvian Health Rapidly Expands TruVerus™ Menu with FDA Clearances for Cardiovascular, Liver, and Core Metabolic Health Tests ...

Eisai And Nuvation Bio Enter Into Exclusive Licensing Agreement For Taletrectinib In Europe And Additional Countries Outside The U.S., China And Japan. Eisai and Nuvation Bio Enter into Exclusive ...

A NEW breast cancer therapy shown to significantly reduce the risk of cancer recurrence and improve disease-free survival in women is now available in ...

Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in ...

U.S. commercial launch in thalassemia underway following December 2025 FDA approvalPre-sNDA meeting with FDA for mitapivat ...